ASCO 2021 Poster Walks
Many thanks to Drs. Kurzrock, Sanford, Jethwa & Loree for taking the time to share their expertise for these Poster Walks!
Session 1:
- LEAP 005 trial: Phase 2 Lenvatinib plus Pembrolizumab
- Neoadjuvant chemo to improve colon cancer survival in resectable metastatic colon cancer- A real world NCDB analysis
Dr. Razelle Kurzrock, a precision medicine expert, discusses the LEAP 005 trial and the real world study on the role of neoadjuvant chemo in resectable metastatic CRC. Colorectal cancer patients from COLONTOWN participate in this in-depth conversation.
We also have a follow-up conversation in COLONTOWN with our clinical trials curator Adrian Terek; if you are a member of our MSS trials neighborhood be sure to check out that discussion.
Session 2.:
- CtDNA to predict recurrence of metastatic CRC following surgery or radiation
- Phase 2 PANDORA trial: Capecitabine+ concomitant RT followed by durvalumab as preoperative treatment in rectal cancer
Dr. Nina Sanford, a radiation oncologist, discusses data from an observational study to assess the value of ctDNA (liquid biopsy) in predicting recurrence of metastatic CRC after surgery or radiation. The 2nd poster covers the PANDORA trial for rectal cancer.
Session 3:
- Survival and organ preservation according to clinical response after TNT in locally advanced rectal cancer patients, a secondary analysis from the OPRA trial
- Phase 2 PANDORA trial: Capecitabine+ concomitant RT followed by durvalumab as preoperative treatment in rectal cancer
Dr. Krishan Jethwa, a radiation oncologist, discusses the OPRA trial, and also reviews proton therapy for rectal cancer in this conversation. He has a slightly different take on the PANDORA trial.
Session 4:
Dr. Loree, with BC Canada, discusses several posters, including one also discussed by Dr. Sanford in Session 2 (#2 here, beginning at 40 minutes into the video)